{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:44:52Z","timestamp":1768913092708,"version":"3.49.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.mcna.2018.02.010","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T11:35:06Z","timestamp":1529408106000},"page":"697-714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["New and Emerging Illicit Psychoactive Substances"],"prefix":"10.1016","volume":"102","author":[{"given":"Ryan","family":"Graddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan E.","family":"Buresh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darius A.","family":"Rastegar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mcna.2018.02.010_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa1610300","article-title":"\u201cZombie\u201d outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York","volume":"376","author":"Adams","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2018.02.010_bib2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.amjmed.2015.10.008","article-title":"Top 10 facts you need to know about synthetic cannabinoids: not so nice spice","volume":"129","author":"Kemp","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.mcna.2018.02.010_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00204-013-1163-9","article-title":"Khat and synthetic cathinones: a review","volume":"88","author":"Valente","year":"2014","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/7854_2016_61","article-title":"Clinical pharmacology of the synthetic cathinone mephedrone","volume":"32","author":"Papaseit","year":"2017","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.mcna.2018.02.010_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20174","article-title":"Novel psychoactive substances of interest for psychiatry","volume":"14","author":"Schifano","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.mcna.2018.02.010_bib6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/YCO.0000000000000066","article-title":"Mephedrone and other cathinones","volume":"27","author":"Zawilska","year":"2014","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.mcna.2018.02.010_bib7","first-page":"109","article-title":"Synthetic cathinone abuse","volume":"5","author":"Capriola","year":"2013","journal-title":"Clin Pharmacol Adv Appl"},{"key":"10.1016\/j.mcna.2018.02.010_bib8","unstructured":"3,4-Methylenedioxypyrovalerone (MDPV). (2013). [online] Drug Enforcement Administration Office of Diversion Control. Available at: https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/mdpv.pdf. Accessed July 18, 2017."},{"key":"10.1016\/j.mcna.2018.02.010_bib9","unstructured":"3,4-Methylenedioxymethcathinone (Methylone). (2013). [online] Drug Enforcement Administration Office of Diversion Control. Available at: https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/methylone.pdf. Accessed July 18, 2017."},{"key":"10.1016\/j.mcna.2018.02.010_bib10","unstructured":"112th Congress. Synthetic Drug Control Act of 2012, S3190. Senate, Washington, DC, May 16, 2012."},{"key":"10.1016\/j.mcna.2018.02.010_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/1570159X13666141210224137","article-title":"Synthetic cathinones: a new public health problem","volume":"13","author":"Karila","year":"2015","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.mcna.2018.02.010_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.08.028","article-title":"Self-reported use of novel psychoactive substances in a US nationally representative survey: prevalence, correlates, and a call for new survey methods to prevent underreporting","volume":"156","author":"Palamar","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1016\/j.mcna.2018.02.010_bib13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/dar.12372","article-title":"Novel psychoactive substance use by US adolescents: characteristics associated with use of synthetic cannabinoids and synthetic cathinones","volume":"35","author":"Patrick","year":"2016","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.mcna.2018.02.010_bib14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1360-0443.2010.03130.x","article-title":"Mephedrone, new kid for the chop?","volume":"106","author":"Winstock","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.mcna.2018.02.010_bib15","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1360-0443.2011.03502.x","article-title":"Mephedrone: use, subjective effects and health risks","volume":"106","author":"Winstock","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.mcna.2018.02.010_bib16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.drugalcdep.2016.02.001","article-title":"Detection of \u201cbath salts\u201d and other novel psychoactive substances in hair samples of ecstasy\/MDMA\/\u201cMolly\u201d users","volume":"161","author":"Palamar","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.010_bib17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/dta.312","article-title":"The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone)","volume":"3","author":"Dargan","year":"2011","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.mcna.2018.02.010_bib18","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1038\/npp.2016.75","article-title":"Human pharmacology of mephedrone in comparison with MDMA","volume":"41","author":"Papaseit","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.mcna.2018.02.010_bib19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.4088\/JCP.12cr07819","article-title":"\u201cBath salts\u201d\u2013induced psychosis and serotonin toxicity","volume":"73","author":"Joksovic","year":"2012","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.mcna.2018.02.010_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2013.06.016","article-title":"Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports","volume":"132","author":"Miotto","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.010_bib21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/emj.2010.092288","article-title":"Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone","volume":"28","author":"Wood","year":"2011","journal-title":"Emerg Med J"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.010_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13181-014-0451-y","article-title":"Prevalence of rhabdomyolysis in sympathomimetic toxicity: a comparison of stimulants","volume":"11","author":"O\u2019Connor","year":"2015","journal-title":"J\u00a0Med Toxicol"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.010_bib23","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14740338.4.6.1145","article-title":"The potential adverse effects of habitual use of Catha edulis (khat)","volume":"4","author":"Al-Habori","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.mcna.2018.02.010_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.drugalcdep.2011.02.011","article-title":"A\u00a0web-based survey on mephedrone","volume":"118","author":"Carhart-Harris","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.010_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.brainresbull.2016.03.005","article-title":"The effects and risks associated to mephedrone and methylone in humans: a review of the preliminary evidences","volume":"126","author":"Karila","year":"2016","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.mcna.2018.02.010_bib26","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jemermed.2013.11.104","article-title":"Synthetic cathinones (\u201cBath salts\u201d)","volume":"46","author":"Banks","year":"2014","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.mcna.2018.02.010_bib27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/dta.1633","article-title":"Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology","volume":"6","author":"Ellefsen","year":"2015","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.mcna.2018.02.010_bib28","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.mayocp.2016.12.007","article-title":"Clinical interpretation of urine drug tests: what clinicians need to know about urine drug screens","volume":"92","author":"Moeller","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.mcna.2018.02.010_bib29","doi-asserted-by":"crossref","first-page":"9437","DOI":"10.1007\/s00216-013-7386-z","article-title":"Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry","volume":"405","author":"Concheiro","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.mcna.2018.02.010_bib30","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00216-012-6548-8","article-title":"Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS\/MS analysis","volume":"405","author":"Swortwood","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.mcna.2018.02.010_bib31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3109\/00952990.2012.694535","article-title":"Intoxication delirium following use of synthetic cathinone derivatives","volume":"38","author":"Penders","year":"2012","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.mcna.2018.02.010_bib32","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/15563650.2011.590812","article-title":"Clinical experience with and analytical confirmation of \u201cbath salts\u201d and \u201clegal highs\u201d (synthetic cathinones) in the United States","volume":"49","author":"Spiller","year":"2011","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13181-011-0159-1","article-title":"Seizures and hyponatremia related to ethcathinone and methylone poisoning","volume":"8","author":"Boulanger-Gobeil","year":"2012","journal-title":"J\u00a0Med Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3949\/ccjm.79a.11147","article-title":"Synthetic legal intoxicating drugs: the emerging \u201cincense\u201d and \u201cbath salt\u201d phenomenon","volume":"79","author":"Jerry","year":"2012","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.mcna.2018.02.010_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/0897190014544814","article-title":"Toxicology and management of novel psychoactive drugs","volume":"28","author":"Kersten","year":"2015","journal-title":"J\u00a0Pharm Pract"},{"key":"10.1016\/j.mcna.2018.02.010_bib36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.annemergmed.2011.11.033","article-title":"Serotonin syndrome associated with MDPV use: a case report","volume":"60","author":"Mugele","year":"2012","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.mcna.2018.02.010_bib37","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pnpbp.2012.05.022","article-title":"The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): a brief review","volume":"39","author":"Corkery","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.mcna.2018.02.010_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/1570159X13666141210222409","article-title":"Recreational use, analysis and toxicity of tryptamines","volume":"13","author":"Tittarelli","year":"2015","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.mcna.2018.02.010_bib39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2045125316689030","article-title":"Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies","volume":"7","author":"dos Santos","year":"2017","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.mcna.2018.02.010_bib40","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/jat\/29.5.394","article-title":"Fatality due to acute alpha-methyltryptamine intoxication","volume":"29","author":"Boland","year":"2005","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib41","unstructured":"Drug Enforcement Administration Office of Diversion Control. 3,4-Methylenedioxypyrovalerone (MDPV). (2013). [online] Drug Enforcement Administration Office of Diversion Control. Available at: https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/methylone.pdf. Accessed July 18, 2017."},{"issue":"3","key":"10.1016\/j.mcna.2018.02.010_bib42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1055\/s-0043-102059","article-title":"New psychoactive substances (NPS) - a challenge for the addiction treatment services","volume":"50","author":"Scherbaum","year":"2017","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.010_bib43","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.mcna.2018.02.010_bib44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2013.09.011","article-title":"Psychoactive substances\u2014some new, some old: a scan of the situation in the U.S","volume":"134","author":"Maxwell","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.010_bib45","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00204-015-1513-x","article-title":"The hallucinogenic world of tryptamines: an updated review","volume":"89","author":"Araujo","year":"2015","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib46","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s00204-016-1812-x","article-title":"New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics","volume":"90","author":"Meyer","year":"2016","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib47","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.forsciint.2005.11.026","article-title":"A\u00a0fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, foxy","volume":"163","author":"Tanaka","year":"2006","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.mcna.2018.02.010_bib48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/15563650.2011.572076","article-title":"The clinical toxicology of the designer \u201cparty pills\u201d benzylpiperazine and trifluoromethylphenylpiperazine","volume":"49","author":"Schep","year":"2011","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib49","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/09595230801956140","article-title":"Patterns of benzylpiperazine\/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand","volume":"27","author":"Wilkins","year":"2008","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.mcna.2018.02.010_bib50","unstructured":"Drug Enforcement Administration Office of Diversion Control. N-benzylpiperazine. Available at: https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/bzp.pdf. Accessed July 18, 2017."},{"key":"10.1016\/j.mcna.2018.02.010_bib51","unstructured":"1-[3-(Trifluoro-methyl)-phenyl]piperazine. (2013). [online] Drug Enforcement Administration Office of Diversion Control. Available at: https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/tfmpp.pdf. Accessed July 18, 2017."},{"issue":"3","key":"10.1016\/j.mcna.2018.02.010_bib52","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.drugalcdep.2011.10.007","article-title":"Piperazine compounds as drugs of abuse","volume":"122","author":"Arbo","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20133","key":"10.1016\/j.mcna.2018.02.010_bib53","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.drugalcdep.2012.06.014","article-title":"The impact of the prohibition of benzylpiperazine (BZP) 'legal highs' on the prevalence of BZP, new legal highs and other drug use in New Zealand","volume":"127","author":"Wilkins","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.010_bib54","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.scitotenv.2016.09.152","article-title":"Occurrence of new psychoactive substances in wastewater of major Chinese cities","volume":"575","author":"Gao","year":"2017","journal-title":"Sci Total Environ"},{"key":"10.1016\/j.mcna.2018.02.010_bib55","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/dta.285","article-title":"Subjective effects in humans following administration of party pill drugs BZP and TFMPP alone and in combination","volume":"3","author":"Lin","year":"2011","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.mcna.2018.02.010_bib56","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/phar.1424","article-title":"\u201cNot for human consumption\u201d: a review of emerging designer drugs","volume":"34","author":"Musselman","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.mcna.2018.02.010_bib57","first-page":"35","article-title":"Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand","volume":"118","author":"Gee","year":"2005","journal-title":"N\u00a0Z Med J"},{"key":"10.1016\/j.mcna.2018.02.010_bib58","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/15563650802307602","article-title":"Toxicity from the recreational use of 1-benzylpiperazine","volume":"46","author":"Gee","year":"2008","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib59","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jat\/32.2.172","article-title":"Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP","volume":"32","author":"Elliott","year":"2008","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib60","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s13181-013-0295-x","article-title":"2C or not 2C: phenethylamine designer drug review","volume":"9","author":"Dean","year":"2013","journal-title":"J\u00a0Med Toxicol"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.010_bib61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/01480545.2014.911882","article-title":"2C-I-NBOMe, an \u201cN-bomb\u201d that kills with \u201csmiles\u201d","volume":"38","author":"Nikolau","year":"2015","journal-title":"Drug Chem Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.emc.2013.09.001","article-title":"Emerging drugs of abuse","volume":"32","author":"Nelson","year":"2014","journal-title":"Emerg Med Clin North Am"},{"key":"10.1016\/j.mcna.2018.02.010_bib63","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0269881111431752","article-title":"4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects","volume":"7","author":"Caudevilla-G\u00e1lligo","year":"2012","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.mcna.2018.02.010_bib64","unstructured":"4-Bromo-2,5-Dimethoxyphenethylamine. (2013). [online] Drug Enforcement Administration Office of Diversion Control. Available at: https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/bromo_dmp.pdf. Accessed July 18, 2017."},{"key":"10.1016\/j.mcna.2018.02.010_bib65","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/00952990701202970","article-title":"\u201cResearch chemicals\u201d: tryptamine and phenethylamine use among high-risk youth","volume":"43","author":"Sanders","year":"2008","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.mcna.2018.02.010_bib66","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3109\/15563650.2011.615318","article-title":"Clinical toxicology of newer recreational drugs","volume":"49","author":"Hill","year":"2011","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib67","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jat\/27.7.493","article-title":"Postmortem identification and quantitation of 2,5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD","volume":"27","author":"Curtis","year":"2003","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib68","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s13181-013-0287-x","article-title":"Recurrent seizures and serotonin syndrome following \u201c2C-I\u201d ingestion","volume":"9","author":"Bosak","year":"2013","journal-title":"J\u00a0Med Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib69","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/jms.1558","article-title":"\u2018Spice\u2019 and other herbal blends: harmless incense of cannabinoid designer drugs?","volume":"44","author":"Auwarter","year":"2009","journal-title":"J\u00a0Mass Spectrom"},{"key":"10.1016\/j.mcna.2018.02.010_bib70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/jcph.827","article-title":"The pharmacologic and clinical effects of illicit synthetic cannabinoids","volume":"57","author":"White","year":"2017","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.mcna.2018.02.010_bib71","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","article-title":"Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications","volume":"144","author":"Castaneto","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.010_bib72","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lfs.2013.09.017","article-title":"Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to \u03949-THC: mechanism underlying greater toxicity?","volume":"97","author":"Fantegrossi","year":"2014","journal-title":"Life Sci"},{"key":"10.1016\/j.mcna.2018.02.010_bib73","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/7854_2016_60","article-title":"Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites","volume":"32","author":"Tai","year":"2017","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.mcna.2018.02.010_bib74","first-page":"618","article-title":"Centers for Disease Control (CDC). Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid Use - United States, January-May 2015","volume":"64","author":"Law","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.mcna.2018.02.010_bib75","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.15585\/mmwr.mm6540a4","article-title":"Increase in adverse reactions associated with use of synthetic cannabinoids - Anchorage, Alaska, 2015-2016","volume":"65","author":"Springer","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.mcna.2018.02.010_bib76","unstructured":"DEA, Controlled Substances Act, 1308.11 Schedule I. Available at: https:\/\/www.deadiversion.usdoj.gov\/21cfr\/cfr\/1308\/1308_11.htm. Accessed July 31, 2017."},{"key":"10.1016\/j.mcna.2018.02.010_bib77","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.drugalcdep.2015.01.044","article-title":"Synthetic cannabinoid use in a nationally representative sample of US high school seniors","volume":"149","author":"Palamar","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.010_bib78","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/08897077.2014.959151","article-title":"Synthetic cannabinoids: use and predictors in a community sample of young adults","volume":"36","author":"Caviness","year":"2015","journal-title":"Subst Abus"},{"key":"10.1016\/j.mcna.2018.02.010_bib79","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.drugalcdep.2016.07.018","article-title":"Age, period, and cohort effects in synthetic cannabinoid use among US adolescents, 2011-2015","volume":"166","author":"Keyes","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.010_bib80","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1056\/NEJMc1313655","article-title":"An outbreak of exposure to a novel synthetic cannabinoid","volume":"370","author":"Monte","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"39","key":"10.1016\/j.mcna.2018.02.010_bib81","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.15585\/mmwr.mm6439a7","article-title":"Severe illness associated with reported use of synthetic cannabinoids - Mississippi, April 2015","volume":"64","author":"Kasper","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.mcna.2018.02.010_bib82","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1521-0391.2012.00240.x","article-title":"\"Spice\" and \"K2\" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans","volume":"21","author":"Gunderson","year":"2012","journal-title":"Am J Addict"},{"key":"10.1016\/j.mcna.2018.02.010_bib83","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/0269881115574493","article-title":"Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample","volume":"29","author":"Winstock","year":"2015","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.mcna.2018.02.010_bib84","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1177\/0269881116658990","article-title":"Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis","volume":"30","author":"Bassir Nia","year":"2016","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.mcna.2018.02.010_bib85","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1360-0443.2012.04078.x","article-title":"Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings","volume":"108","author":"Hermanns-Clausen","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.mcna.2018.02.010_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","article-title":"A\u00a0systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment","volume":"54","author":"Tait","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.mcna.2018.02.010_bib87","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/1039856216663733","article-title":"Signs and symptoms associated with synthetic cannabinoid toxicity: systematic review","volume":"24","author":"Courts","year":"2015","journal-title":"Australas Psychiatry"},{"key":"10.1016\/j.mcna.2018.02.010_bib88","doi-asserted-by":"crossref","DOI":"10.7812\/TPP\/16-160","article-title":"Spice-y kidney failure: a case report and systematic review of acute kidney injury attributable to the use of synthetic cannabis","volume":"21","author":"Zarifi","year":"2017","journal-title":"Perm J"},{"key":"10.1016\/j.mcna.2018.02.010_bib89","first-page":"256","article-title":"Acute rhabdomyolysis following synthetic cannabinoid ingestion","volume":"8","author":"Adedinsewo","year":"2016","journal-title":"N\u00a0Am J Med Sci"},{"key":"10.1016\/j.mcna.2018.02.010_bib90","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.07.030","article-title":"Synthetic cannabis and acute ischemic stroke","volume":"23","author":"Bernson-Leung","year":"2014","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.mcna.2018.02.010_bib91","doi-asserted-by":"crossref","first-page":"e1622","DOI":"10.1542\/peds.2010-3823","article-title":"Myocardial infarction associated with use of the synthetic cannabinoid K2","volume":"128","author":"Mir","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.mcna.2018.02.010_bib92","doi-asserted-by":"crossref","first-page":"940.e5-6","DOI":"10.1016\/j.ajem.2017.01.011","article-title":"Profound hypotension and bradycardia in the setting of synthetic cannabinoid intoxication - A case series","volume":"35","author":"Andonian","year":"2017","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.mcna.2018.02.010_bib93","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jemermed.2015.10.009","article-title":"Synthetic cannabinoids and their effects on the cardiovascular system","volume":"50","author":"Von Der Haar","year":"2016","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.mcna.2018.02.010_bib94","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pnpbp.2012.04.017","article-title":"Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids","volume":"39","author":"Seely","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.mcna.2018.02.010_bib95","first-page":"296","article-title":"The synthetic cannabinoid withdrawal syndrome","volume":"7","author":"Nacca","year":"2013","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.mcna.2018.02.010_bib96","first-page":"464","article-title":"Withdrawal phenomena and dependence syndrome after the consumption of \u201cspice gold\u201d","volume":"106","author":"Zimmermann","year":"2009","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.mcna.2018.02.010_bib97","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dar.12225","article-title":"Synthetic cannabinoid withdrawal: a new demand on detoxification services","volume":"34","author":"Macfarlane","year":"2015","journal-title":"Drug Alcohol Rev"},{"issue":"9","key":"10.1016\/j.mcna.2018.02.010_bib98","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1515\/cclm-2016-0831","article-title":"Immunoassay screening in urine for synthetic cannabinoids - an evaluation of the diagnostic efficiency","volume":"55","author":"Franz","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.mcna.2018.02.010_bib99","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11419-015-0270-0","article-title":"Comprehensive review of the detection methods for synthetic cannabinoids and cathinones","volume":"33","author":"Namera","year":"2015","journal-title":"Forensic Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib100","series-title":"Influx of fentanyl-laced counterfeit pill and toxic fentanyl-related compounds further increases risk of fentanyl-related overdose and fatalities","first-page":"00395","author":"Centers for Disease Control and Prevention","year":"2016"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.010_bib101","first-page":"256","article-title":"Misuse of novel synthetic opioids: a deadly new trend","volume":"11","author":"Prekupec","year":"2017","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.mcna.2018.02.010_bib102","first-page":"761","article-title":"An acute ocfentanil fatality: a case report with postmortem concentrations","volume":"40","author":"Dussy","year":"2016","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib103","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ajem.2010.03.003","article-title":"Carfentanil\u2013an ultra potent opioid","volume":"28","author":"George","year":"2010","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.mcna.2018.02.010_bib104","unstructured":"Emerging threat report: Annual 2016. (2017). [online] Drug Enforcement Administration. Available at: https:\/\/ndews.umd.edu\/sites\/ndews.umd.edu\/files\/emerging-threat-report-2016-annual.pdf. Accessed June 4, 2017."},{"key":"10.1016\/j.mcna.2018.02.010_bib105","unstructured":"Drug Enforcement Administration. Emerging threat report: first quarter 2017."},{"key":"10.1016\/j.mcna.2018.02.010_bib106","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.forsciint.2016.09.006","article-title":"Blood concentrations of new designer benzodiazepines in forensic cases","volume":"268","author":"H\u00f8iseth","year":"2016","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.mcna.2018.02.010_bib107","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jat\/bkv122","article-title":"ELISA detection of phenazepam, etizolam, pyrazolam, flubormazepam, diclazepam, and delorazepam in blood using Immunalysis benzodiazepine kit","volume":"40","author":"O\u2019Connor","year":"2016","journal-title":"J\u00a0Anal Toxicol"},{"key":"10.1016\/j.mcna.2018.02.010_bib108","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.annemergmed.2014.12.019","article-title":"Overdose of etizolam: the abuse and risk of a benzodiazepine analog","volume":"65","author":"O\u2019Connell","year":"2015","journal-title":"Ann Emerg Med"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518300142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518300142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T23:15:20Z","timestamp":1661469320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712518300142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":108,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0025712518300142"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2018.02.010","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New and Emerging Illicit Psychoactive Substances","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2018.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}